330
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 - was completed in just 11 years, with approval being received approximately 5 years after the initiation of the first Phase I trial.

          Related collections

          Author and article information

          Journal
          Nat Rev Drug Discov
          Nature reviews. Drug discovery
          Springer Science and Business Media LLC
          1474-1776
          1474-1776
          Oct 2006
          : 5
          : 10
          Affiliations
          [1 ] Department of Cancer Research, Bayer Pharmaceuticals Corp., West Haven, Connecticut 06516, USA. scott.wilhelm.b@bayer.com
          Article
          nrd2130
          10.1038/nrd2130
          17016424
          14462479-0ba1-49e5-9d84-dabef08bd04c
          History

          Comments

          Comment on this article